On April 29, 2026, Avory & Company, LLC disclosed in a U.S. Securities and Exchange Commission (SEC) filing that it sold 156,571 shares of Omnicell (OMCL +1.97%), an estimated $6.55 million transaction based on the quarterly average price.
What happened
According to its SEC filing dated April 29, 2026, Avory & Company, LLC reduced its position in Omnicell by 156,571 shares, an estimated $6.55 million transaction based on the average first-quarter 2026 closing price. The quarter-end value of the Omnicell stake declined by $8.01 million, a figure that reflects both the reduction in shares and Omnicell’s price movement over the period. The fund’s post-sale holding in Omnicell was 77,137 shares, valued at $2.57 million.
What else to know
Following the sale, Omnicell represents 3.33% of Avory & Company, LLC’s reportable assets under management.
Top five holdings after the filing:
- NYSEMKT: VOO: $17.22 million (22.3% of AUM)
- NASDAQ: ZM: $8.59 million (11.1% of AUM)
- NYSE: XYZ: $7.41 million (9.6% of AUM)
- BATS: AVRY: $7.29 million (9.4% of AUM)
- NASDAQ: Z: $4.27 million (5.5% of AUM)
As of April 28, 2026, Omnicell shares were priced at $45.51, up 47.6% over the past year, outperforming the S&P 500 by 18.45 percentage points.
Company overview
| Metric | Value |
|---|---|
| Revenue (TTM) | $1.19 billion |
| Net income (TTM) | $2.052 million |
| Market capitalization | $2.07 billion |
| Price (as of market close April 28, 2026) | $45.51 |
Company snapshot
- Omnicell provides medication management solutions, including automated dispensing systems, pharmacy automation, and adherence packaging for healthcare systems and pharmacies
- The company generates revenue primarily through the sale and servicing of automation equipment, software solutions, and related consumables that optimize medication distribution and inventory management
- Its primary customers are hospitals, health systems, institutional pharmacies, and retail pharmacies seeking to improve medication safety, efficiency, and regulatory compliance
Omnicell operates at scale in the healthcare technology sector, serving over 3,600 employees and generating more than $1.20 billion in annual revenue. The company's strategy centers on delivering integrated automation and software solutions that streamline medication management across care settings. Omnicell's competitive edge lies in its comprehensive product suite and focus on workflow automation, which enables healthcare providers to enhance patient safety and operational efficiency.
What this transaction means for investors
Avory & Company, a Florida-based investment advisor, recently disclosed the sale of approximately $6.6 million worth of Omnicell stock during the first quarter (the three months ending on March 31, 2026). Here are some key takeaways for investors.
First, Omnicell stock has struggled over the last few years. Since 2021, shares have declined by 68%, with a compound annual growth rate (CAGR) of -20.8%. That’s well below the return produced by the S&P 500 over the same period — a 83% total return and a CAGR of 12.8%.
At any rate, Omnicell recently reported strong first-quarter earnings, led by $310 million in revenue (up 15% year-over-year). Net income was $11 million, up from a net loss of -$7 million one year ago.
In summary, Omnicell stock is enjoying a boost from a positive earnings report. However, the stock’s long-term track record of underperformance may give some investors pause.
